Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Icu Medical (ICUI) Income towards Parent Company (2016 - 2025)

Icu Medical's Income towards Parent Company history spans 17 years, with the latest figure at -$13.2 million for Q4 2025.

  • For the quarter ending Q4 2025, Income towards Parent Company rose 44.4% year-over-year to -$13.2 million, compared with a TTM value of $1.9 million through Dec 2025, up 101.63%, and an annual FY2025 reading of $1.9 million, up 101.63% over the prior year.
  • Income towards Parent Company for Q4 2025 was -$13.2 million at Icu Medical, down from -$1.9 million in the prior quarter.
  • The five-year high for Income towards Parent Company was $32.5 million in Q2 2025, with the low at -$39.5 million in Q1 2024.
  • Average Income towards Parent Company over 5 years is -$5.8 million, with a median of -$11.6 million recorded in 2022.
  • Year-over-year, Income towards Parent Company crashed 555.69% in 2024 and then soared 251.83% in 2025.
  • Tracing ICUI's Income towards Parent Company over 5 years: stood at $19.9 million in 2021, then crashed by 177.97% to -$15.5 million in 2022, then fell by 10.37% to -$17.1 million in 2023, then crashed by 38.96% to -$23.8 million in 2024, then soared by 44.4% to -$13.2 million in 2025.
  • Per Business Quant, the three most recent readings for ICUI's Income towards Parent Company are -$13.2 million (Q4 2025), -$1.9 million (Q3 2025), and $32.5 million (Q2 2025).